Background: Prior studies suggest that activation of the tryptophan catabolism via the
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Figure 1, printed in colour
Introduction
Major depression (MD) is a severe and potentially life-threatening psychiatric illness that accounts for a large part of the overall global burden of disease [1] . The neurobiology of depression is complex and not fully understood [2] . However, it has been shown that MD often is associated with increased levels of pro-inflammatory cytokines, suggestive of a mild to moderate immune and inflammation activation [3, 4] .
The kynurenine pathway of tryptophan metabolism [5] (Figure 1 ) has been proposed as a link between inflammatory processes and depressive symptoms [6, 7] . The essential amino acid tryptophan is mainly (90%) metabolised to kynurenine (Kyn) and a small portion serves as precursor of serotonin. Conversion of tryptophan to kynurenine is regulated by tryptophan 2,3-dioxygenase (TDO) and indole 2,3-dioxygenase (IDO). The activity of IDO is stimulated by proinflammatory cytokines, especially interferon gamma (INF-γ), but also tumor necrosis factor alpha (TNF-α) and interleukin-6, whereas TDO is activated mainly by cortisol [8] .
Through activation of IDO, inflammation leads to enhanced catabolism of tryptophan via the kynurenine pathway. The kynurenine to tryptophan ratio (KTR) functions as a proxy measure of INF-γ mediated activation of cellular immunity and this ratio has been shown to correlate positively with the concentration of other immune markers, like neopterin an established marker of cellular immune activation [9] . However, while conversion of tryptophan towards kynurenine is induced by both IFN-γ, through up-regulation of IDO, and by TDO, formation of neopterin is induced by IFN-γ only. Thus, circulating concentrations of neopterin are considered more specific to immune activation than is KTR. Kyn is metabolised further by the M A N U S C R I P T
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enzyme kynurenine aminotransferase (KAT) to kynurenic acid (KA), an N-methyl-d-aspartate receptor (NMDAr) antagonist and neuroprotective agent [8] , or by kynurenine 3-monooxygenase (KMO) to 3-hydroxykynurenine (HK). HK is then metabolised through 3-hydroxyanthranilic acid (HAA) to either picolinic acid (Pic) or quinolinic acid (QA). Both HK and the NMDAr agonist QA are thought to exert neurotoxic effects [8] . Like IDO, KMO is activated by proinflammatory cytokines, directing metabolism through the neurotoxic branch of the kynurenine pathway and thus disrupting the balance between neuroprotective KA and the neurotoxic metabolites HK and QA [8, 10] . Several steps in the kynurenine pathway are dependent on the coenzymes pyridoxal 5'-phosphate (PLP), the active form of vitamin B6, and flavine adenine dinucleotide (FAD), the active form of riboflavin (vitamin B2) [11] (Figure 1 ). The serum level of these vitamins is affected by smoking [12] . Cotinine, a metabolite of nicotine, is a commonly used serum marker of recent nicotine exposure [13] .
The status of the kynurenine pathway can be described by a set of ratios starting with KTR as a marker of the first and rate-limiting step catalysed by INF-γ-responsive enzyme, IDO. The direction of the Kyn breakdown and the flux through the downstream enzymes, KAT and KMO, are reflected by KA/Kyn and HK/Kyn, while KA/HK and KA/QA reflect the balance between the two main branches of the pathway [14] . Several studies have shown that MD patients have significantly lower plasma concentration of KA and lower KA/KYN and KA/QA than healthy controls, indicating altered balance in favour of neurotoxic metabolites [6, [14] [15] [16] [17] . The ratio XA/HK is a useful marker for vitamin B6 [18] , an important coenzyme in several steps in the kynurenine pathway. Finally, the enzyme aminocarboxymuconate semialdehyde decarboxylase (ACMSD) limits QA formation by competitive production of the putative neuroprotective metabolite Pic. It has been suggested that QA might induce suicidal symptoms by affecting glutamate neurotransmission [19] . Furthermore, a study assessing the M A N U S C R I P T
CFS and plasma Pic to QA ratio in suicide attempters supported the hypothesis that a reduced ACMSD activity underlies excess of neurotoxic QA production observed in patients exhibiting suicidal behavior [20] . The ratio of Pic and QA (Pic/QA) can be used as an estimate of ACMSD activity.
Electroconvulsive therapy (ECT) is considered the most effective treatment option for severe or treatment resistant MD [21] . It has been suggested that ECT may act by modulating immunological mechanisms [22] [23] [24] . Studies on how ECT impacts the immune system have indicated that a single session of ECT might induce an acute activation of immune response [25] [26] [27] , while repetitive ECT treatment can down-regulate proinflammatory markers [27] [28] [29] .
Through this immunomodulating effect, ECT might also affect the tryptophan metabolism [24] . Studies suggest that ECT in MD patients might shift the tryptophan metabolism towards metabolites with neuroprotective properties, with increase in KA and KA/HK [22] and decrease in QA after treatment with ECT [16] . However, other studies found no significant changes in KA [30] or in KYN, KA and KA/KYN [17] .
The aim of this study was to investigate serum concentrations of tryptophan and a large panel of kynurenine pathway metabolites in MD patients referred to ECT in comparison with healthy controls and to explore the effect of ECT on the kynurenine pathway over a whole course of ECT.
Material and methods
Study design
In this prospective, observational study we collected blood samples and assessed the severity of depressive symptoms in major depression patients before and after a series of ECT.
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Additionally, the study included a group of age-and sex-matched healthy controls that contributed with the same baseline data. The study protocol has previously been reported in detail [31] .
Ethical considerations
The study was approved by the Regional Committee for Medical Research Ethics in South East Norway (2013/1032). All participants provided informed written consent to participate in the study. 
ECT treatment
All patients received the standard ECT treatment as it is provided at the ECT-department at the Haukeland University Hospital in Bergen, Norway, administered with right unilateral electrode placement and a Thymatron System IV device (Somatics Inc., Venice, FL, USA), providing brief-or ultra-brief-pulse (0.25-0.5 ms), square wave, constant current (900 mA).
Anaesthesia was obtained with the short acting anaesthetic thiopental. Muscle relaxation was obtained with succinylcholine (1 mg/kg). Three sessions per week were given until remission or until no further improvement of symptoms was expected, with a maximum of 20 sessions.
The initial stimulus dose was determined based on age, and subsequent adjustments were made after each treatment based on electroencephalographic parameters such as seizure duration, δ-waves and postictal suppression, as well as reorientation time and clinical effect.
Assessments
Symptom intensity was measured with Montgomery and Åsberg Depression Rating Scale (MADRS) [32] by the treating clinician before and after completed ECT-series. Response was defined as a reduction of more than 50% in MADRS score over the treatment series, and remission as a MADRS score lower than 10 after ECT.
Blood samples
Venous blood samples were collected after at least 8 hours of fasting at two time points for each patient: prior to treatment and one to two weeks after the completed ECT-series (median Within-day and between-day CVs were 4-7 % for QA and Pic, precision data for the other biomarkers analysed by this assay can be found in previous publication [34] . The renal function marker creatinine was also measured at baseline for evaluation of renal function [34] .
Statistical analyses
Statistical analyses were performed using the Statistical Package for the Social Sciences (SPSS) version 23.0 (IBM Corp., Armonk, New York) and RStudio version 1.1.383 [35] with core package stats and additional packages Tidyverse and ggsignif. Baseline clinical data for controls and patients were compared using chi-square test for categorical variables and MannWhitney U test for continuous variables. Baseline biochemical data were compared using linear regression for log-transformed variables both unadjusted and adjusted for smoking using log-transformed levels of cotinine. Changes in patients' serum concentrations from before to after treatment were analysed using Wilcoxon paired test. The same analyses were also performed for patients divided in subgroups based on ECT response and remission.
Results
Demographics and clinical characteristics
Out of the 30 patients recruited, three were excluded -one due to missing baseline blood Table 1 . Table 1 ECT treatment variables and symptom severity before and after treatment
Anesthesia was given with a median of 3.88 (IQR = 1.88) mg thiopental per kg body weight.
ECT was delivered with a median charge of 237. 
Tryptophan metabolites in patients and controls
The comparison of serum concentrations of tryptophan and metabolites for patients and the age and gender matched healthy controls are given in 
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higher while XA, KA/Kyn, KA/QA, XA/HK and Pic/QA were lower in the patient group compared to controls. Table 3) . There was also a significant increase in neopterin concentration both in responders and non-responders. Other metabolites concentrations and ratios remained unchanged. Analyses in remitters (n = 8) showed the same direction of effect as in patients with treatment response though no changes were significant. In the nonremitters (n = 13) there were significantly increased levels of neopterin (Supplementary table   2 ).
Figure 2, printed in colour.
Discussion
This study aimed to investigate serum concentrations of kynurenine metabolites in MD patients referred to ECT in comparison with healthy controls and to assess the effect of ECT on the kynurenine pathway. There were three main findings: ii) Comparing post-treatment to baseline concentrations, there was no reduction of KTR as a proxy measure for inflammation, nor in the concentration of inflammation marker neopterin.
On the contrary, the concentration of neopterin was significantly increased after ECT.
iii) After treatment there was an increase in patient concentrations of HAA and Pic, metabolites with putative neuroprotective properties, and in the Pic to QA ratio.
Altered kynurenine pathway metabolism has been proposed as a link between mild chronic inflammation and depressive symptoms [5] [6] [7] . Inflammation can affect the kynurenine pathway both by activation of IDO, reflected by an increased KTR, and by activation of KMO, increasing metabolism through the HK branch of the pathway and causing an imbalance between neuroprotective and neurotoxic metabolites. In our study, like in a recent meta-analysis [36] , there was no significant difference in KTR between healthy controls and patients with MD in the unadjusted analyses. However, adjusted for cotinine, KTR was higher in patients, indicating increased INF-γ mediated activation of cellular immunity. Furthermore, there were lower levels of KA, XA and Pic, and lower KA/Kyn and KA/QA in patients compared to controls. This is in line with other studies on blood and CSF samples from depressed or suicidal patients showing an imbalance in the kynurenine pathway in favour of neurotoxic metabolites [6, 14-17, 30, 37, 38] . Comparing patients with healthy controls, these studies have shown higher levels of neurotoxic kynurenines [37, 38] , lower levels of neuroprotective kynurenines [6, 17, 30, 38] and altered kynurenine ratios with lower KA/Kyn [6, 17] and KA/QA [14] [15] [16] . However, one study found normal levels of kynurenines in depressed patients compared to healthy controls [39] .
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ECT has been found to elevate KTR in a study with 23 patients with MD [40] . Like two other studies assessing changes of KTR during ECT [16, 17] , we found no such change in KTR after treatment. However, after treatment we found significant increase in the patient concentrations of the inflammation marker neopterin, indicating an inflammatory response.
Inflammation as response to ECT has been demonstrated in several studies [24] . Increased levels of proinflammatory cytokines have been observed as a short-term effect of single ECT sessions [25] [26] [27] . In our study, the post-treatment blood sample was drawn several days (median = 10 days, IQR = 6 days) after the last session in a series of ECT. Full series of ECT treatments like this have mostly been associated with a decrease in inflammation markers [27] [28] [29] . However, in a study by Hoekstra et al. a significant increase in neopterin serum concentration was detected in 20 severely depressed patients after ECT series [41] . Similarly, after a series of ECT, Freire and colleagues found increased levels of the proinflammatory cytokines TNF-α and INF-γ, both potent activators of kynurenine pathway enzymes IDO and KMO, although IL-6 concentration was reduced [42] .
Previous studies on changes in the balance between neuroprotective and neurotoxic kynurenines after ECT have yielded inconsistent results: Schwieler and colleagues [16] reported a reduction in QA as well as in QA/KA in blood samples from 19 patients after ECT treatment. In addition to increased KTR, Guloksuz and colleagues found increased levels of KA, KA/Kyn and KA/HK after ECT [40] . In contrast, Olajossy and colleagues [30] found low levels of KA in pre-treatment blood samples of 50 patients across three diagnostic groups, but no significant increase in KA after treatment. Similarly, Allen and colleagues [17] found low plasma concentrations of KA and low KA/Kyn in patients before treatment, but no increase in KA after treatment, independent of response status. In the current study, only two M A N U S C R I P T
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kynurenine metabolites, HAA and Pic, were significantly increased after treatment. These metabolites both belong to the KMO branch of the kynurenine pathway starting with the KMO mediated conversion of Kyn to HK. It is interesting to note that both Pic and HAA are proposed as neuroprotective substances and that Pic is though of as an escape route preventing high levels of the neurotoxic QA (Figure 1 ) [20, 43, 44] .
In sum, it is possible that an ECT associated inflammation response has caused increased metabolism through KMO and the neurotoxic branch of the kynurenine pathway. KMO is stimulated by the same pro-inflammatory cytokines that cause activation of neopterin producing macrophages [9, 10] , and higher KMO activity could explain the observed increase in HAA and Pic.
To our knowledge this is the first study assessing a large panel of metabolites of the kynurenine pathway of tryptophan degradation and metabolite ratios reflecting enzymes involved in patients with MD before and after ECT treatment. The kynurenine pathway represents a potential mechanistic link between low-grade inflammation in depression and neuroplasticity. However, the small sample size, the lack of a control group of depressed patients not receiving ECT, and the complex contribution of the various kynurenine metabolites to the pathogenesis of depression, make it difficult to distinguish the antidepressant mechanisms of action of ECT from other, nonspecific effects. Furthermore, there are important variables, such as systemic inflammation, nutrition, BMI and time of blood sampling, which could affect the tryptophan metabolism that we were unable to adjust for in this study. We excluded patients with renal failure, which may increase plasma concentration of metabolites with high renal clearance. Patients with somatic disorders other than renal failure were not excluded, and medications for somatic and psychiatric disorder M A N U S C R I P T
may possibly affect concentrations of some metabolites. However, for each individual, medication was essentially stable during the study period, as only minor changes were done in drug therapy, mainly reduction of benzodiazepines and other substances raising seizure threshold. Compared to population-based studies [45] , the response and remission rate in the current study are relatively low. This is probably due to a selection bias, as the included patients were younger and had a longer duration of the current episode, both factors known to be associated with lower response rates. The small sample size is a limitation of the study, as is the heterogeneous study population consisting of both bipolar and unipolar depression patients. The statistical power and the ability to detect "true" associations may be further reduced by normal variation in metabolite concentration over time [46] , and such attenuations are likely because metabolite concentration was measured only at a single time point before and after ECT. However, the ability to detect biomarker status from a single measurement has been evaluated in terms of intraclass correlation constants (ICCs) for most kynurenine investigated, and ICCs varies in the range from 0.5 to 0.7 [47] , which is considered as moderate to strong within-subject reproducibility [48] .
In summary, the current study explored the impact of ECT on a large panel of kynurenine metabolites possibly involved in the pathogenesis of depression. The results from the current study are preliminary and should be followed up by studies in larger cohorts, also including a control group of depressed patients not receiving ECT. 
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